Search

Your search keyword '"Bozec, Erwan"' showing total 483 results
Start Over Author "Bozec, Erwan"
483 results on '"Bozec, Erwan"'

4. Machine Learning-Derived Echocardiographic Phenotypes Predict Heart Failure Incidence in Asymptomatic Individuals

Author

Kobayashi, Masatake, Huttin, Olivier, Magnusson, Martin, Ferreira, João Pedro, Bozec, Erwan, Huby, Anne-Cecile, Preud’homme, Gregoire, Duarte, Kevin, Lamiral, Zohra, Dalleau, Kevin, Bresso, Emmanuel, Smaïl-Tabbone, Malika, Devignes, Marie-Dominique, Nilsson, Peter M., Leosdottir, Margret, Boivin, Jean-Marc, Zannad, Faiez, Rossignol, Patrick, and Girerd, Nicolas

Published
2022
Full Text
View/download PDF

7. Proteomic profiles of left atrial volume and its influence on response to spironolactone: Findings from the HOMAGE trial and STANISLAS cohort.

Author

Kobayashi, Masatake, Ferreira, João Pedro, Duarte, Kevin, Bresso, Emmanuel, Huttin, Olivier, Bozec, Erwan, Brunner La Rocca, Hans‐Peter, Delles, Christian, Clark, Andrew L., Edelmann, Frank, González, Arantxa, Heymans, Stephane, Pellicori, Pierpaolo, Petutschnigg, Johannes, Verdonschot, Job A.J., Rossignol, Patrick, Cleland, John G.F., Zannad, Faiez, and Girerd, Nicolas

Subjects
BRAIN natriuretic factor, LEFT heart atrium, SOMATOMEDIN, PROTEOMICS, SPIRONOLACTONE
Abstract

Aims: High left ventricular filling pressure increases left atrial volume and causes myocardial fibrosis, which may decrease with spironolactone. We studied clinical and proteomic characteristics associated with left atrial volume indexed by body surface area (LAVi), and whether LAVi influences the response to spironolactone on biomarker expression and clinical variables. Methods and results: In the HOMAGE trial, where people at risk of heart failure were randomized to spironolactone or control, we analysed 421 participants with available LAVi and 276 proteomic measurements (Olink) at baseline, month 1 and 9 (mean age 73 ± 6 years; women 26%; LAVi 32 ± 9 ml/m2). Circulating proteins associated with LAVi were also assessed in asymptomatic individuals from a population‐based cohort (STANISLAS; n = 1640; mean age 49 ± 14 years; women 51%; LAVi 23 ± 7 ml/m2). In both studies, greater LAVi was significantly associated with greater left ventricular masses and volumes. In HOMAGE, after adjustment and correction for multiple testing, greater LAVi was associated with higher concentrations of matrix metallopeptidase‐2 (MMP‐2), insulin‐like growth factor binding protein‐2 (IGFBP‐2) and N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) (false discovery rates [FDR] <0.05). These associations were externally replicated in STANISLAS (all FDR <0.05). Among these biomarkers, spironolactone decreased concentrations of MMP‐2 and NT‐proBNP, regardless of baseline LAVi (pinteraction > 0.10). Spironolactone also significantly reduced LAVi, improved left ventricular ejection fraction, lowered E/e', blood pressure and serum procollagen type I C‐terminal propeptide (PICP) concentration, a collagen synthesis marker, regardless of baseline LAVi (pinteraction > 0.10). Conclusion: In individuals without heart failure, LAVi was associated with MMP‐2, IGFBP‐2 and NT‐proBNP. Spironolactone reduced these biomarker concentrations as well as LAVi and PICP, irrespective of left atrial size. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Role of aldosterone in the mid‐ and long‐term left ventricular remodelling after acute myocardial infarction: the REMI study

Author

Monzo, Luca, primary, Huttin, Olivier, additional, Ferreira, João Pedro, additional, Lamiral, Zohra, additional, Bozec, Erwan, additional, Beaumont, Marine, additional, Micard, Emilien, additional, Baudry, Guillaume, additional, Marie, Pierre‐Yves, additional, Eschalier, Romain, additional, Rossignol, Patrick, additional, Zannad, Faiez, additional, and Girerd, Nicolas, additional

Published
2023
Full Text
View/download PDF

10. Associations of childhood adiposity with adult intima–media thickness and inflammation: a 20-year longitudinal population-based cohort

Author

Fujikawa, Tomona, Kobayashi, Masatake, Wagner, Sandra, Duarte, Kevin, Scherdel, Pauline, Heude, Barbara, Dupont, Vincent, Bozec, Erwan, Bresso, Emmanuel, Zannad, Faiez, Rossignol, Patrick, Girerd, Nicolas, Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre d'investigation clinique plurithématique Pierre Drouin [Nancy] (CIC-P), Centre d'investigation clinique [Nancy] (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy] (INI-CRCT), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy], French-Clinical Research Infrastructure Network - F-CRIN [Paris] (Cardiovascular & Renal Clinical Trialists - CRCT ), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Equipe 6 : ORCHAD - Origines précoces de la santé du développement de l'enfant (CRESS - U1153), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Conservatoire National des Arts et Métiers [CNAM] (CNAM), Centre Hospitalier Universitaire de Reims (CHU Reims), ANR-15-RHUS-0004,FIGHT-HF,Combattre l'insuffisance cardiaque(2015), ANR-15-IDEX-0004,LUE,Isite LUE(2015), European Project, European Project: 305507,EC:FP7:HEALTH,FP7-HEALTH-2012-INNOVATION-1,HOMAGE(2013), and European Project: ERA-CVD/0001/2016,MINOTAUR

Subjects
inflammation, Physiology, [SDV]Life Sciences [q-bio], childhood adiposity, Internal Medicine, biomarkers, Cardiology and Cardiovascular Medicine, carotid intima–media thickness
Abstract

International audience; Background: The associations between childhood adiposity and adult increased carotid intima-media thickness (cIMT) have been well established, which might be corroborated by the association between adiposity in children and inflammation in adults. However, longitudinal data regarding biological pathways associated with childhood adiposity are lacking.Methods: The current study included participants from the STANISLAS cohort who had adiposity measurements at age 5-18 years [ N = 519, mean (SD) age, 13.0 (2.9) years; 46.4% male], and who were measured with cIMT, vascular-related and metabolic-related proteins at a median follow-up of 19 ± 2 years. BMI, waist-to-height ratio and waist circumference were converted to age-specific and sex-specific z -scores.Results: A minority of children were overweight/obese (16.2% overweight-BMI z -score >1; 1.3% obesity- z -score >2). Higher BMI, waist-height ratio and waist circumference in children were significantly associated with greater adult cIMT in univariable analysis, although not after adjusting for C-reactive protein. These associations were more pronounced in those with consistently high adiposity status from childhood to middle adulthood. Participants with higher adiposity during childhood (BMI or waist-height ratio) had higher levels of insulin-like growth factor-binding protein-1, protein-2, matrix metalloproteinase-3, osteopontin, hemoglobin and C-reactive protein in adulthood. Network analysis showed that IL-6, insulin-like growth factor-1 and fibronectin were the key proteins associated with childhood adiposity.Conclusion: In a population-based cohort followed for 20 years, higher BMI or waist-to-height ratio in childhood was significantly associated with greater cIMT and enhanced levels of proteins reflective of inflammation, supporting the importance of inflammation as progressive atherosclerosis in childhood adiposity.

Published
2022
Full Text
View/download PDF

12. Layer myocardial strain is the most heritable echocardiographic trait

Author

Huttin, Olivier, primary, Xhaard, Constance, additional, Dandine-Roulland, Claire, additional, Le Floch, Edith, additional, Bacq-Daian, Delphine, additional, Lamiral, Zohra, additional, Bozec, Erwan, additional, Deleuze, Jean-François, additional, Zannad, Faiez, additional, Rossignol, Patrick, additional, and Girerd, Nicolas, additional

Published
2023
Full Text
View/download PDF

14. Birth weight and subclinical cardiovascular and renal damage in a population-based study (the STANISLAS cohort study)

Author

Lopez-Sublet, Marilucy, primary, Merkling, Thomas, additional, Girerd, Nicolas, additional, Xhaard, Constance, additional, Flahault, Adrien, additional, Bozec, Erwan, additional, Leroy, Celine, additional, Fujikawa, Tomona, additional, Vaag, Allan Arthur, additional, Mebazaa, Alexandre, additional, Kistorp, Caroline Michaela, additional, Heude, Barbara, additional, Boivin, Jean Marc, additional, Zannad, Faiez, additional, Wagner, Sandra, additional, and Rossignol, Patrick, additional

Published
2023
Full Text
View/download PDF

15. Role of aldosterone in mid‐ and long‐term left ventricular remodelling after acute myocardial infarction: The REMI study.

Author

Monzo, Luca, Huttin, Olivier, Ferreira, João Pedro, Lamiral, Zohra, Bozec, Erwan, Beaumont, Marine, Micard, Emilien, Baudry, Guillaume, Marie, Pierre‐Yves, Eschalier, Romain, Rossignol, Patrick, Zannad, Faiez, and Girerd, Nicolas

Subjects
MYOCARDIAL infarction, VENTRICULAR remodeling, CARDIAC magnetic resonance imaging, ALDOSTERONE, RENIN-angiotensin system
Abstract

Aims: Whether aldosterone levels after myocardial infarction (MI) are associated with mid‐ and long‐term left ventricular (LV) remodelling in the era of systematic use of renin–angiotensin system inhibitors is uncertain. We prospectively investigated the relationship between aldosterone levels and mid‐ and long‐term LV remodelling in patients with acute MI. Methods and results: Plasma aldosterone was measured in 119 patients successfully treated by primary percutaneous coronary angioplasty for a first acute ST‐elevation MI (STEMI) 2–4 days after the acute event. LV volumes were assessed by cardiac magnetic resonance (CMR) and transthoracic echocardiography (TTE) in the same timeframe and 6 months later. LV assessment was repeated by TTE 3–9 years after MI (n = 80). The median aldosterone level at baseline was 23.1 [16.8; 33.1] pg/ml. In the multivariable model, higher post‐MI aldosterone concentration was significantly associated with more pronounced increase in LV end‐diastolic volume index (TTE: β ± standard error [SE]: 0.113 ± 0.046, p = 0.015; CMR: β ± SE: 0.098 ± 0.040, p = 0.015) and LV end‐systolic volume index (TTE: β ± SE: 0.083 ± 0.030, p = 0.008; CMR: β ± SE: 0.064 ± 0.032, p = 0.048) at 6‐month follow‐up, regardless of the method of assessment. This result was consistent also in patients with a LV ejection fraction (LVEF) >40%. The association between baseline plasma aldosterone and adverse LV remodelling did not persist at the 3–9‐year follow‐up evaluation. Conclusion: Aldosterone concentration in the acute phase was associated with adverse LV remodelling in the medium term, even in the subgroup of patients with LVEF >40%, suggesting a potential role of the mineralocorticoid system in post‐MI adverse remodelling. Plasma aldosterone was no longer associated with LV remodelling in the long term (NCT01109225). [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

20. Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials

Author

Ferreira, João Pedro, primary, Cleland, John G., additional, Girerd, Nicolas, additional, Bozec, Erwan, additional, Rossignol, Patrick, additional, Pellicori, Pierpaolo, additional, Cosmi, Franco, additional, Mariottoni, Beatrice, additional, Solomon, Scott D., additional, Pitt, Bertram, additional, Pfeffer, Marc A., additional, Shah, Amil M., additional, Petutschnigg, Johannes, additional, Pieske, Burkert, additional, Edelmann, Frank, additional, and Zannad, Faiez, additional

Published
2022
Full Text
View/download PDF

22. The effect of camelina oil on vascular function in essential hypertensive patients with metabolic syndrome

Author

Bellien, Jeremy, Bozec, Erwan, Bounoure, Frédéric, Khettab, Hakim, Malloizel-Delaunay, Julie, Skiba, Mohamed, Iacob, Michèle, Donnadieu, Nathalie, Coquard, Aude, Morio, Béatrice, Laillet, Brigitte, Rigaudière, Jean-Paul, Chardigny, Jean-Michel, Monteil, Christelle, Vendeville, Cathy, Mercier, Alain, Cailleux, Anne-Françoise, Blanchard, Anne, Amar, Jacques, Fezeu, Léopold, Pannier, Bruno, Bura-Rivière, Alessandra, Boutouyrie, Pierre, Joannidès, Robinson, BOZEC, Erwan, Service de pharmacologie [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Centre d'Investigation Clinique [CHU Rouen] (CIC Rouen), Hôpital Charles Nicolle [Rouen], Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Endothélium, valvulopathies et insuffisance cardiaque (EnVI), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'investigation clinique plurithématique Pierre Drouin [Nancy] (CIC-P), Centre d'investigation clinique [Nancy] (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Paris-Centre de Recherche Cardiovasculaire (PARCC (UMR_S 970/ U970)), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Différenciation et communication neuronale et neuroendocrine (DC2N), Service de pharmacie [CHU HEGP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Service de Médecine Vasculaire [CHU Toulouse], Pôle Cardiovasculaire et Métabolique [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Pharmacie [CHU Rouen], Centre de Recherche en Nutrition Humaine Auvergne [CHU Clermont-Ferrand] (CRNH A), Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), CHU Clermont-Ferrand-CHU Clermont-Ferrand, Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Unité de Nutrition Humaine (UNH), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Clermont Auvergne (UCA), UFR Santé, Médecine et Biologie Humaine (UFR SMBH), Université Sorbonne Paris Nord, CIC - HEGP (CIC 1418), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Service d'hypertension artérielle et thérapeutique [CHU Toulouse] (HTA et thérapeutique), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Service de Néphrologie [CH Manhès, Fleury-Mérogis], Centre Hospitalier Manhès [Fleury-Mérogis], INSERM UMR_S 970, Team 7 : Cellular, Molecular and Physiological Mechanisms of Heart Failure, and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Hôpital Européen Georges Pompidou [APHP] (HEGP)

Subjects
Pathologic, Cyclodextrins, Eicosapentaenoic acid, Camelina oil, Insulin resistance, Vascular function, Metabolic syndrome, Dilatation, Essential hypertension, C-reactive protein, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Cardiovascular system, Plasma, Fluid flow, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Metabolic syndrome x, Hypertension, Lipds, Thiobarbituric acid reactive substances, Endothelium, Alpha-linolenic acid
Abstract

International audience; Background The effects of a dietary supplementation with the vegetable omega-3 α-linolenic acid (ALA) on cardiovascular homeostasis are unclear. In this context, it would be interesting to assess the effects of camelina oil. Objective This study aimed to assess the cardiovascular and metabolic effects of camelina oil in hypertensive patients with metabolic syndrome. Methods In a double-blind placebo-controlled randomized study, treated essential hypertensive patients with metabolic syndrome received during 6 months either cyclodextrin-complexed camelina oil containing ≈ 1.5 g ALA/day (n = 40), or an isocaloric placebo (n = 41), consisting in the same quantity of cyclodextrins and wheat starch. Anthropometric data, plasma lipids, glycemia, insulinemia, creatininemia, thiobarbituric acid reactive substances, high-sensitivity C-reactive protein, and n-3, n-6 and n-9 fatty acids in erythrocyte membranes were measured. Peripheral and central blood pressures, arterial stiffness, carotid intima-media thickness and brachial artery endothelium-dependent flow-mediated dilatation and endothelium-independent dilatation were assessed. Results Compared to placebo, camelina oil increased ALA (mean ± SD: 0 ± 0.04 vs. 0.08 ± 0.06%, P

Published
2022
Full Text
View/download PDF

23. Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the HOMAGE trial

Author

Ferreira, João Pedro, Verdonschot, Job, Girerd, Nicolas, Bozec, Erwan, Pellicori, Pierpaolo, Collier, Timothy, Mariottoni, Beatrice, Cosmi, Franco, Hazebroek, Mark, Cuthbert, Joe, Petutschnigg, Johannes, Heymans, Stephane, Staessen, Jan, Pieske, Burkert, Edelman, Frank, Clark, Andrew, Díez, Javier, González, Arantxa, Rossignol, Patrick, Cleland, John, Zannad, Faiez, BOZEC, Erwan, Heart OMics in AGEing - HOMAGE - - EC:FP7:HEALTH2013-02-01 - 2019-01-31 - 305507 - VALID, Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre d'investigation clinique plurithématique Pierre Drouin [Nancy] (CIC-P), Centre d'investigation clinique [Nancy] (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy] (INI-CRCT), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy], Faculdade de Medicina da Universidade do Porto (FMUP), Universidade do Porto = University of Porto, Maastricht University Medical Centre (MUMC), Maastricht University [Maastricht], University of Glasgow, London School of Hygiene and Tropical Medicine (LSHTM), Cortona Hospital, University of Hull [United Kingdom], Charité Campus Virchow-Klinikum (CVK), German Center for Cardiovascular Research (DZHK), Berlin Institute of Health (BIH), Studies Coordinating Centre [Louvain, Belgique], Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), Institute of Health Carlos III, Universidad de Navarra [Pamplona] (UNAV), and European Project: 305507,EC:FP7:HEALTH,FP7-HEALTH-2012-INNOVATION-1,HOMAGE(2013)

Subjects
spironolactone, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, inflammation, fibrosis, cardiovascular system, cardiovascular diseases, ejection fraction, circulatory and respiratory physiology, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system
Abstract

International audience; Background: Left ventricular ejection fraction (LVEF) can provide hemodynamic information and may influence the response to spironolactone and other heart failure (HF) therapies.Aims: To study the patient characteristics and circulating protein associations with LVEF, and whether LVEF influenced the response to spironolactone.Methods: HOMAGE enrolled patients aged >60 years at high risk of developing HF with a LVEF ≥45%. 527 patients were randomized to either spironolactone or standard-of-care for ≈9 months. 276 circulating proteins were measured using Olink® technology.Results: 364 patients had available LVEF determined by the Simpson's bi-plane method. The respective LVEF tertiles were: Tertile1:65% (N = 121). Patients with a LVEF>65% had smaller LV chamber size and volumes, and lower natriuretic peptide levels. Compared to patients with a LVEF65% had higher levels of circulating c-c motif chemokine ligand-23 and interleukin-8, and lower levels of tissue plasminogen activator, BNP, S100 calcium binding protein A12, and collagen type I alpha 1 chain (COL1A1). Spironolactone significantly reduced the circulating levels of BNP and COL1A1 without significant treatment-by-LVEF heterogeneity: BNP change β = -0.36 Log2 and COL1A1 change β = -0.16 Log2 (P < 0.0001 for both; interactionP>0.1 for both). Spironolactone increased LVEF from baseline to month 9 by 1.1%, P = 0.007.Conclusion: Patients with higher LVEF had higher circulating levels of chemokines and inflammatory markers and lower levels of stretch, injury, and fibrosis markers. Spironolactone reduced the circulating levels of natriuretic peptides and type 1 collagen, and increased LVEF. This article is protected by copyright. All rights reserved.

Published
2022
Full Text
View/download PDF

26. Dyskalemia in people at increased risk for heart failure: findings from the heart ‘OMics’ in AGEing (HOMAGE) trial

Author

Monzo, Luca, primary, Ferreira, João Pedro, additional, Cleland, John G.F., additional, Pellicori, Pierpaolo, additional, Mariottoni, Beatrice, additional, Verdonschot, Job A.J., additional, Hazebroek, Mark R., additional, Collier, Tim J., additional, Cuthbert, Joe J., additional, Pieske, Burkert, additional, Edelmann, Frank, additional, Petutschnigg, Johannes, additional, Khan, Javed, additional, Ahmed, Fozia Z., additional, Girerd, Nicolas, additional, Bozec, Erwan, additional, Díez, Javier, additional, González, Arantxa, additional, Clark, Andrew L., additional, Cosmi, Franco, additional, Staessen, Jan A., additional, Heymans, Stephane, additional, Rossignol, Patrick, additional, and Zannad, Faiez, additional

Published
2022
Full Text
View/download PDF

28. Fatty acid desaturase genetic variations and dietary omega-3 fatty acid intake associate with arterial stiffness

Author

Bäck, Magnus, Xhaard, Constance, Rouget, Raphael, Thuillier, Quentin, Plunde, Oscar, Larsson, Susanna C., Girerd, Nicolas, Ferreira, João Pedro, Boivin, Jean-Marc, Bozec, Erwan, Mercklé, Ludovic, Zannad, Faiez, Hoge, Axelle, Guillaume, Michèle, Dandine-Roulland, Claire, Floch, Edith Le, Bacq-Daian, Delphine, Deleuze, Jean-François, Van den Berghe, Laurie, Nazare, Julie-Anne, Laville, Martine, Branlant, Christiane, Behm-Ansmant, Isabelle, Wagner, Sandra, Rossignol, Patrick, Bäck, Magnus, Xhaard, Constance, Rouget, Raphael, Thuillier, Quentin, Plunde, Oscar, Larsson, Susanna C., Girerd, Nicolas, Ferreira, João Pedro, Boivin, Jean-Marc, Bozec, Erwan, Mercklé, Ludovic, Zannad, Faiez, Hoge, Axelle, Guillaume, Michèle, Dandine-Roulland, Claire, Floch, Edith Le, Bacq-Daian, Delphine, Deleuze, Jean-François, Van den Berghe, Laurie, Nazare, Julie-Anne, Laville, Martine, Branlant, Christiane, Behm-Ansmant, Isabelle, Wagner, Sandra, and Rossignol, Patrick

Abstract

AIMS: Long-chain polyunsaturated fatty acids (PUFAs) generate diverse bioactive lipid mediators, which tightly regulate vascular inflammation. The effects of omega-3 PUFA supplementation in cardiovascular prevention however remain controversial. In addition to direct dietary intake, fatty acid desaturases (FADS) determine PUFA levels. Increased arterial stiffness represents an independent predictor of mortality and cardiovascular events. The aim of the present study was to determine the association of PUFA intake, FADS1 genotype, and FADS expression with arterial stiffness. METHODS AND RESULTS: A cross-sectional population-based cohort study of 1464 participants without overt cardiovascular disease was conducted. Dietary intake was assessed using a food frequency questionnaire. Arterial stiffness was assessed by carotid-femoral pulse wave velocity (cfPWV), and the FADS1 locus variant was determined. Blood cell transcriptomics was performed in a subset of 410 individuals. Pulse wave velocity was significantly associated with the FADS1 locus variant. Differential associations between PWV and omega-3 PUFA intake were observed depending on the FADS1 genotype. High omega-3 PUFA intake attenuated the FADS1 genotype-dependent associations. Carriers of the minor FADS1 locus variant exhibited increased expression of FADS2, which is associated with PWV. CONCLUSION: Taken together, these findings point to FADS1 genotype-dependent associations of omega-3 PUFA intake on subclinical cardiovascular disease. These findings may have implications for identifying responders and non-responders to omega-3 PUFA supplementation and open up for personalized dietary counselling in cardiovascular prevention.

Published
2022
Full Text
View/download PDF

31. Fatty acid desaturase genetic variations and dietary omega-3 fatty acid intake associate with arterial stiffness

Author

Bäck, Magnus, primary, Xhaard, Constance, additional, Rouget, Raphael, additional, Thuillier, Quentin, additional, Plunde, Oscar, additional, Larsson, Susanna C., additional, Girerd, Nicolas, additional, Ferreira, João Pedro, additional, Boivin, Jean-Marc, additional, Bozec, Erwan, additional, Mercklé, Ludovic, additional, Zannad, Faiez, additional, Hoge, Axelle, additional, Guillaume, Michèle, additional, Dandine-Roulland, Claire, additional, Floch, Edith Le, additional, Bacq-Daian, Delphine, additional, Deleuze, Jean-François, additional, Van den Berghe, Laurie, additional, Nazare, Julie-Anne, additional, Laville, Martine, additional, Branlant, Christiane, additional, Behm-Ansmant, Isabelle, additional, Wagner, Sandra, additional, and Rossignol, Patrick, additional

Published
2022
Full Text
View/download PDF

32. Quality of Beverage Intake and Cardiometabolic and Kidney Outcomes: Insights From the STANISLAS Cohort

Author

Wagner, Sandra, primary, Merkling, Thomas, additional, Girerd, Nicolas, additional, Bozec, Erwan, additional, Van den Berghe, Laurie, additional, Hoge, Axelle, additional, Guillaume, Michèle, additional, Kanbay, Mehmet, additional, Cakir-Kiefer, Céline, additional, Thornton, Simon N., additional, Boivin, Jean-Marc, additional, Mercklé, Ludovic, additional, Laville, Martine, additional, Rossignol, Patrick, additional, and Nazare, Julie-Anne, additional

Published
2022
Full Text
View/download PDF

34. The effect of camelina oil on vascular function in essential hypertensive patients with metabolic syndrome

Author

Bellien, Jeremy, Bozec, Erwan, Bounoure, Frédéric, Khettab, Hakim, Malloizel-Delaunay, Julie, Skiba, Mohamed, Iacob, Michèle, Donnadieu, Nathalie, Coquard, Aude, Morio, Béatrice, Laillet, Brigitte, Rigaudière, Jean-Paul, Chardigny, Jean-Michel, Monteil, Christelle, Vendeville, Cathy, Mercier, Alain, Cailleux, Anne-Françoise, Blanchard, Anne, Amar, Jacques, Fezeu, Léopold, Pannier, Bruno, Bura-Rivière, Alessandra, Boutouyrie, Pierre, Joannidès, Robinson, Service de pharmacologie [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Centre d'Investigation Clinique [CHU Rouen] (CIC Rouen), Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Endothélium, valvulopathies et insuffisance cardiaque (EnVI), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'investigation clinique plurithématique Pierre Drouin [Nancy] (CIC-P), Centre d'investigation clinique [Nancy] (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Paris-Centre de Recherche Cardiovasculaire (PARCC (UMR_S 970/ U970)), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Différenciation et communication neuronale et neuroendocrine (DC2N), Service de Pharmacologie, AP-HP, HEGP, Service de Médecine Vasculaire [CHU Toulouse], Centre Hospitalier Régional Universitaire de Toulouse (CHRU Toulouse), Pharmacie [CHU Rouen], Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Université Clermont Auvergne, CRNH Auvergne, UFR Santé, Médecine et Biologie Humaine (UFR SMBH), Université Sorbonne Paris Nord, Centre d'Investigation Clinique (CIC)-INSERM 1404, CIC - HEGP (CIC 1418), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Department of Arterial Hypertension, Toulouse University III, Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Department of Nephrology, Centre Hospitalier F.H. Manhès, Université de Paris, Service de Pharmacologie, INSERM U970, équipe 7, Hôpital Charles Nicolle [Rouen], Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Service de pharmacie [CHU HEGP], Pôle Cardiovasculaire et Métabolique [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre de Recherche en Nutrition Humaine Auvergne [CHU Clermont-Ferrand] (CRNH A), Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), CHU Clermont-Ferrand-CHU Clermont-Ferrand, Unité de Nutrition Humaine (UNH), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Clermont Auvergne (UCA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Service d'hypertension artérielle et thérapeutique [CHU Toulouse] (HTA et thérapeutique), Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Service de Néphrologie [CH Manhès, Fleury-Mérogis], Centre Hospitalier Manhès [Fleury-Mérogis], Biologie et pharmacologie de l'insuffisence cardiaque = Cellular, Molecular and Physiological Mechanisms of Heart Failure, and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Hôpital Européen Georges Pompidou [APHP] (HEGP)

Subjects
Pathologic, Cyclodextrins, Eicosapentaenoic acid, Camelina oil, Insulin resistance, Vascular function, Metabolic syndrome, Dilatation, Essential hypertension, C-reactive protein, Cardiovascular system, Plasma, Fluid flow, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Metabolic syndrome x, Hypertension, Lipds, Thiobarbituric acid reactive substances, Endothelium, Alpha-linolenic acid
Abstract

International audience; Background The effects of a dietary supplementation with the vegetable omega-3 α-linolenic acid (ALA) on cardiovascular homeostasis are unclear. In this context, it would be interesting to assess the effects of camelina oil. Objective This study aimed to assess the cardiovascular and metabolic effects of camelina oil in hypertensive patients with metabolic syndrome. Methods In a double-blind placebo-controlled randomized study, treated essential hypertensive patients with metabolic syndrome received during 6 months either cyclodextrin-complexed camelina oil containing ≈ 1.5 g ALA/day (n = 40), or an isocaloric placebo (n = 41), consisting in the same quantity of cyclodextrins and wheat starch. Anthropometric data, plasma lipids, glycemia, insulinemia, creatininemia, thiobarbituric acid reactive substances, high-sensitivity C-reactive protein, and n-3, n-6 and n-9 fatty acids in erythrocyte membranes were measured. Peripheral and central blood pressures, arterial stiffness, carotid intima-media thickness and brachial artery endothelium-dependent flow-mediated dilatation and endothelium-independent dilatation were assessed. Results Compared to placebo, camelina oil increased ALA (mean ± SD: 0 ± 0.04 vs. 0.08 ± 0.06%, P

Published
2021
Full Text
View/download PDF

36. Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials.

Author

Ferreira, João Pedro, Cleland, John G., Girerd, Nicolas, Bozec, Erwan, Rossignol, Patrick, Pellicori, Pierpaolo, Cosmi, Franco, Mariottoni, Beatrice, Solomon, Scott D., Pitt, Bertram, Pfeffer, Marc A., Shah, Amil M., Petutschnigg, Johannes, Pieske, Burkert, Edelmann, Frank, and Zannad, Faiez

Subjects
HEART failure patients, VENTRICULAR ejection fraction, SPIRONOLACTONE, LEFT heart atrium, ANALYSIS of covariance
Abstract

Aims: Spironolactone is currently used in a large proportion of patients with heart failure and preserved ejection fraction (HFpEF), yet its effect on cardiac structure and function in a large population has not been well established. The aim of this study was to evaluate the impact of spironolactone on key echocardiographic parameters in HFpEF. Methods and results: An individual‐patient‐data meta‐analysis of three randomized trials (HOMAGE, Aldo‐DHF, and TOPCAT) was performed comparing spironolactone (9–12 month exposure) to placebo (or control) for the changes in left atrial volume index (LAVi), left ventricular mass index (LVMi), interventricular septum (IVS) thickness, E/e′ ratio, and left ventricular ejection fraction (LVEF) among patients with stage B (HOMAGE) or C (Aldo‐DHF and TOPCAT) HFpEF. Analysis of covariance was used to test the effect of spironolactone on echocardiographic changes. A total of 984 patients were included in this analysis: 452 (45.9%) from HOMAGE, 398 (40.4%) from Aldo‐DHF, and 134 (13.6%) from TOPCAT. The pooled‐cohort patient's median age was 71 (66–77) years and 39% were women. Median LAVi was 29 (24–35) ml/m2, LVMi 100 (84–118) g/m2, IVS thickness 12 (10–13) mm, E/e′ ratio 11 (9–13), and LVEF 64 (59–69)%. Spironolactone reduced LAVi by −1.1 (−2.0 to −0.1) ml/m2 (p = 0.03); LVMi by −3.6 (−6.4 to −0.8) g/m2 (p = 0.01); IVS thickness by −0.2 (−0.3 to −0.1) mm (p = 0.01); E/e′ ratio by −1.3 (−2.4 to −0.2) (p = 0.02); and increased LVEF by 1.7 (0.8–2.6)% (p < 0.01). No treatment‐by‐study heterogeneity was found except for E/e′ ratio with a larger effect in Aldo‐DHF and TOPCAT (interaction p < 0.01). Conclusions: Spironolactone improved cardiac structure and function of patients with HFpEF. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

37. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial

Author

Ong, Kim-Thanh, Perdu, Jérôme, De Backer, Julie, Bozec, Erwan, Collignon, Patrick, Emmerich, Joseph, Fauret, Anne-Laure, Fiessinger, Jean-Noël, Germain, Dominique P, Georgesco, Gabriella, Hulot, Jean-Sebastien, De Paepe, Anne, Plauchu, Henri, Jeunemaitre, Xavier, Laurent, Stéphane, and Boutouyrie, Pierre

Published
2010
Full Text
View/download PDF

39. Genetics of severe hypercholesterolemia in the general population: Insights from the STANISLAS cohort

Author

Xhaard, Constance, primary, Ferreira, João Pedro, additional, Le Floch, Edith, additional, Lamiral, Zohra, additional, Dandine-Roulland, Claire, additional, Bacq-Daian, Delphine, additional, Bozec, Erwan, additional, Boivin, Jean-Marc, additional, Girerd, Nicolas, additional, Deleuze, Jean-François, additional, Zannad, Faiez, additional, and Rossignol, Patrick, additional

Published
2021
Full Text
View/download PDF

40. Cardiac Remodeling and Diastolic Dysfunction in Paroxysmal Atrial Fibrillation

Author

Noirclerc, Nathalie, primary, Huttin, Olivier, additional, de Chillou, Christian, additional, Selton-Suty, Christine, additional, Fillipetti, Laura, additional, Sellal, Jean Marc, additional, Bozec, Erwan, additional, Donal, Erwan, additional, Lamiral, Zohra, additional, Kobayashi, Masatake, additional, Ferreira, João Pedro, additional, Rossignol, Patrick, additional, and Girerd, Nicolas, additional

Published
2021
Full Text
View/download PDF

41. The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial.

Author

Kobayashi, Masatake, Girerd, Nicolas, Ferreira, João Pedro, Kevin, Duarte, Huttin, Olivier, González, Arantxa, Bozec, Erwan, Clark, Andrew L., Cosmi, Franco, Cuthbert, Joe, Diez, Javier, Edelmann, Frank, Hazebroek, Mark, Heymans, Stephane, Mariottoni, Beatrice, Pellicori, Pierpaolo, Petutschnigg, Johannes, Pieske, Burkert, Staessen, Jan A., and Verdonschot, Job A.J.

Abstract

Aims: Procollagen type I C‐terminal propeptide (PICP) and procollagen type III N‐terminal propeptide (PIIINP) are markers reflecting collagen synthesis in cardiac fibrosis. However, they may be influenced by the presence of non‐cardiac comorbidities (e.g. ageing, obesity, renal impairment). Understanding the associations between markers of collagen synthesis and abnormalities of cardiac structure and function is important to screen for myocardial fibrosis and monitor the antifibrotic effect of medications. Methods and results: The HOMAGE (Heart 'OMics' in AGEing) trial showed that spironolactone decreased serum PICP concentrations and improved cardiac remodelling over 9 months in a population at risk of developing heart failure (HF). We evaluated the associations between echocardiographic variables, PICP, PIIINP and galectin‐3 at baseline and during the course of the trial. Among 527 individuals (74 ± 7 years, 26% women), median serum concentrations of PICP, PIIINP and galectin‐3 were 80.6 μg/L (65.1–97.0), 3.9 μg/L (3.1–5.0), and 16.1 μg/L (13.5–19.7), respectively. After adjustment for potential confounders, higher serum PICP was significantly associated with left ventricular hypertrophy, left atrial enlargement, and greater ventricular stiffness (all p < 0.05), whereas serum PIIINP and galectin‐3 were not (all p > 0.05). In patients treated with spironolactone, a reduction in serum PICP during the trial was associated with a decrease in E/e′ (adjusted‐beta = 0.93, 95% confidence interval 0.14–1.73; p = 0.022). Conclusions: In individuals at high risk of developing HF, serum PICP was associated with cardiac structural and functional abnormalities, and a decrease in PICP with spironolactone was correlated with improved diastolic dysfunction as assessed by E/e′. In contrast, no such associations were present for serum PIIINP and galectin‐3. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

43. Circulating multimarker approach to identify patients with preclinical left ventricular remodelling and/or diastolic dysfunction

Author

Huttin, Olivier, primary, Kobayashi, Masatake, additional, Ferreira, João Pedro, additional, Coiro, Stefano, additional, Bozec, Erwan, additional, Selton‐Suty, Christine, additional, Filipetti, Laura, additional, Lamiral, Zohra, additional, Rossignol, Patrick, additional, Zannad, Faiez, additional, and Girerd, Nicolas, additional

Published
2021
Full Text
View/download PDF

46. Subclinical ventricular dysfunction in rheumatoid arthritis

Author

Rodrigues, Patrícia, primary, Ferreira, Betânia, additional, Fonseca, Tomás, additional, Costa, Rita Quelhas, additional, Cabral, Sofia, additional, Pinto, João Loureiro, additional, Saraiva, Francisca, additional, Marinho, António, additional, Huttin, Olivier, additional, Girerd, Nicolas, additional, Bozec, Erwan, additional, Carvalho, Henrique Cyrne, additional, and Ferreira, João Pedro, additional

Published
2020
Full Text
View/download PDF

47. Left ventricular myocardial deformation pattern, mechanical dispersion, and their relation with electrocardiogram markers in the large population-based STANISLAS cohort: insights into electromechanical coupling

Author

Verdugo-Marchese, Mario, primary, Coiro, Stefano, additional, Selton-Suty, Christine, additional, Kobayashi, Masatake, additional, Bozec, Erwan, additional, Lamiral, Zohra, additional, Venner, Clément, additional, Zannad, Faiez, additional, Rossignol, Patrick, additional, Girerd, Nicolas, additional, and Huttin, Olivier, additional

Published
2020
Full Text
View/download PDF

48. PCSK9 Protein and rs562556 Polymorphism Are Associated With Arterial Plaques in Healthy Middle‐Aged Population: The STANISLAS Cohort

Author

Ferreira, João Pedro, primary, Xhaard, Constance, additional, Lamiral, Zohra, additional, Borges‐Canha, Marta, additional, Neves, João Sérgio, additional, Dandine‐Roulland, Claire, additional, LeFloch, Edith, additional, Deleuze, Jean‐François, additional, Bacq‐Daian, Delphine, additional, Bozec, Erwan, additional, Girerd, Nicolas, additional, Boivin, Jean‐Marc, additional, Zannad, Faiez, additional, and Rossignol, Patrick, additional

Published
2020
Full Text
View/download PDF

49. Association of Dietary Patterns Derived Using Reduced‐Rank Regression With Subclinical Cardiovascular Damage According to Generation and Sex in the STANISLAS Cohort

Author

Wagner, Sandra, primary, Lioret, Sandrine, additional, Girerd, Nicolas, additional, Duarte, Kevin, additional, Lamiral, Zohra, additional, Bozec, Erwan, additional, Van den Berghe, Laurie, additional, Hoge, Axelle, additional, Donneau, Anne‐Françoise, additional, Boivin, Jean‐Marc, additional, Mercklé, Ludovic, additional, Zannad, Faiez, additional, Laville, Martine, additional, Rossignol, Patrick, additional, and Nazare, Julie‐Anne, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results